Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs

Stock Information for Mirati Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mirati Therapeutics Inc.

BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region
New Research: Key Drivers of Growth for Express Scripts Holding, D.R. Horton, Mirati Therapeutics, EchoStar, Toro, and Genesee & Wyoming - Factors of Influence, Major Initiatives and Sustained Production
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
Market Trends Toward New Normal in ONEOK, ServiceNow, Mirati, ImmunoCellular, United Technologies, and USG - Emerging Consolidated Expectations, Analyst Ratings
Mirati Therapeutics Reports Third Quarter 2017 Financial Results
Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.